Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Allergan Moves Into Busy CGRP Class By Buying Merck’s Oral Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Allergan agreed to pay $250 million up front for global rights two investigational oral CGRP antagonists in early clinical development for acute treatment and prevention of migraine. Several rivals are racing to develop injectable CGRP antibodies.

Advertisement

Related Content

Biopharma Quarterly Dealmaking Statistics, Q3 2015
Allergan Comes To Q3 Call With Deal News, But Nothing On Pfizer
Teva “Cautiously Optimistic” On Copaxone Despite Generic
Deal Watch: Allergan Diversifies With Deals For Migraine Therapies, Ophthalmologic Device
Allergan Buys MAP To Chart Migraine Franchise Growth
Merck Gets A Headache: Unexpectedly Halts Development Of Migraine Drug

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078773

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel